Kubota Vision initiates prospective study of PBOS in patients
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that on January 17, 2022, the first patient enrolled and completed the first visit in a prospective study in Japan using our Patient-Based Ophthalmology Suite (PBOS), home optical coherence tomography (OCT)*1) device.
The study is led by Dr. Shozo Sonoda of Kagoshima Sonoda Eye Clinic and Plastic Surgery, targeting approximately 40 subjects to be recruited. The Company will lend its PBOS devices to generate data that will be used to improve the device. Dr. Sonoda is an experienced ophthalmologist specializing in cornea, age-related macular degeneration, glaucoma, and vitreoretinal disease. He is actively involved in the Japanese Society of Ophthalmology, Japanese Association of Ophthalmologists, Japanese Society of Retina and Vitreous, Japanese Society of Ocular Circulation, Japanese Society of Artificial Intelligence in Ophthalmology, Japanese Society of Ophthalmic Surgery, Association for Research in Vision and Ophthalmology, and Japanese Society of Ocular Pharmacology.
Dr Sonoda said: “Innovative medical information and communication technologies are in high demand, especially for home healthcare. We believe that it will soon become possible to collect accurate medical data at home using high-performance but small-scale medical devices. These technologies hold a lot of potential, but there are usability challenges to overcome before actual home implementation. The PBOS works on the same principle as OCT devices used in hospitals, but is developed so that patients can use it themselves at home. We will evaluate patient use of the device and hope to contribute our findings to advance ophthalmology.
Ryo Kubota, MD, PhD, Chairman, President and CEO of Kubota Vision Inc., said, “We are grateful that Dr. Sonoda is interested in our OCT device and sees the potential benefits the device could offer. . We have conducted several studies around the world, and this will be the first where the device will be used for a study in Japan. As a Japanese, I am proud and excited to share the new observations that will come from this study in Japan. »
*1 OCT (Optical Coherence Tomography) is a non-invasive tool that uses light waves to take cross-sectional images of the retina.
About the PBOS
The PBOS is a low-cost, home-based ophthalmic self-monitoring OCT device. This small portable device meets mobile health needs (mHealth*2) applications for self-monitoring of retinal health by patients, at home and in remote areas. PBOS aims to improve ophthalmic treatment outcomes in patients diagnosed and treated for age-related macular degeneration (AMD), diabetic macular edema (DME), and other neovascular retinal diseases. The PBOS is designed to detect incipient disease progression and support patient retreatment prior to irreversible vision loss due to disease progression. The main features are low cost and patient friendly design for direct use by patients at home. The PBOS is designed to capture changes in retinal anatomy. Network connectivity and cloud-based technologies are used to alert patients and their physicians to disease progression and retreatment needs.
*2 mHealth refers to the use of technology and mobile communication devices to improve access to health care information, improve the delivery of routine and emergency health services, and provide diagnostic services.
About Kubota Vision Inc.
Kubota Vision Inc. is a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) which is committed to translating innovation into a diverse portfolio of medicines and devices to preserve and restore the sight of millions of people around the world. Kubota Pharmaceutical Group’s development pipeline includes drug candidates for the treatment of diabetic retinopathy and Stargardt’s disease. The company is also developing a wearable OCT device for monitoring neovascular retinal diseases, for direct use by patients, and a wearable device for monitoring myopia. https://www.kubotavision.com/; https://www.kubotaholdings.co.jp/en/
“Kubota Vision”, the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.